Evidence map›Paper›PMID 26020954›Full record

ArticlePloS one2015

Immunological Basis for Rapid Progression of Diabetes in Older NOD Mouse Recipients Post BM-HSC Transplantation.

Nan Wang, Narendiran Rajasekaran, Tieying Hou, Claudia Macaubas, Elizabeth D Mellins

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nan WangProgram in Immunology, Division of Human Gene Therapy, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Narendiran RajasekaranProgram in Immunology, Division of Human Gene Therapy, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Tieying HouProgram in Immunology, Division of Human Gene Therapy, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Claudia MacaubasProgram in Immunology, Division of Human Gene Therapy, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Elizabeth D MellinsProgram in Immunology, Division of Human Gene Therapy, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.
Stanford University · US

Funding

Spectrum Stanford Center for clinical and Translational Research and EducationUL1TR001085 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$37.1M
Stanford Center for Clinical and Translational Education and Research (SCCTER)UL1UL1RR025744 · NCRR · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2008 to 2011
$22.4M
MHC association in autoimmune arthritisR21AI075253 · NIAID · STANFORD UNIVERSITY · PI MELLINS, ELIZABETH D · 2008 to 2010
$486k
Mechanism of MHC Association with Type 1 DiabetesR21DK079163 · NIDDK · STANFORD UNIVERSITY · PI MELLINS, ELIZABETH D · 2008 to 2009
$435k
Characterization of HLA-DQ2 and HLA-DM interactionF32AI089080 · NIAID · STANFORD UNIVERSITY · PI HOU, TIEYING · 2010 to 2011
$99k
NCATS NIH HHS UL1 TR001085NCRR NIH HHS UL1 RR025744NIAID NIH HHS AI075253NIAID NIH HHS F32 AI089080NIAID NIH HHS F32AI089080NIAID NIH HHS R21 AI075253NIDDK NIH HHS DK079163NIDDK NIH HHS R21 DK079163
6 · The paper itself

Abstract

Type I diabetes (T1D), mediated by autoreactive T cell destruction of insulin-producing islet beta cells, has been treated with bone marrow-derived hematopoietic stem cell (BM-HSC) transplantation. Older non-obese diabetic (NOD) mice recipients (3m, at disease-onset stage) receiving syngeneic BM-HSC progressed more rapidly to end-stage diabetes post-transplantation than younger recipients (4-6w, at disease-initiation stage). FACS analyses showed a higher percentage and absolute number of regulatory T cells (Treg) and lower proportion of proliferating T conventional cells (Tcon) in pancreatic lymph nodes from the resistant mice among the younger recipients compared to the rapid progressors among the older recipients. Treg distribution in spleen, mesenteric lymph nodes (MLN), blood and thymus between the two groups was similar. However, the percentage of thymic Tcon and the proliferation of Tcon in MLN and blood were lower in the young resistants. These results suggest recipient age and associated disease stage as a variable to consider in BM-HSC transplantation for treating T1D.

Indexed as

Hematopoietic Stem Cell TransplantationAgingAnimalsAntigens, CDBiomarkersBlood GlucoseDiabetes Mellitus, Type 1Disease Models, AnimalFemaleForkhead Transcription FactorsGene ExpressionHematopoietic Stem CellsImmunophenotypingLymphocyte CountMiceMice, Inbred NODAntigens, CDBiomarkersBlood GlucoseForkhead Transcription FactorsFoxp3 protein, mouse

Identifiers

PMID26020954
PMCPMC4447290
OpenAlexW411640352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.